Randall Bateman

Dr. Bateman is a Scientific Co-Founding Member of C₂N Diagnostics. He is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine (WUSM). Dr. Bateman attended Case Western Reserve University School of Medicine, earning a medical degree with special emphasis on the neurosciences. He completed a Neurology residency at WUSM and then completed post-doctoral research training with David Holtzman, M.D., and clinical research fellowship training with John C. Morris, M.D. Dr. Bateman’s laboratory investigates the causes, and future diagnosis and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques from basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers of Alzheimer’s disease. Dr. Bateman led the development of the SILK technique, which made it possible to determine that clearance of Ab is impaired in patients with Alzheimer’s disease. Bateman and his colleagues are now studying whether alterations in Ab clearance levels can be used to predict AD years before symptoms become apparent. Dr. Bateman is Associate Director and Clinical Core Leader of the Dominantly Inherited Alzheimer’s Network (DIAN), an international collaboration of leading research centers dedicated to studying autosomal dominant AD (ADAD). He is the Director of the DIAN Therapeutic Trials Unit (TTU), which is leading efforts to launch clinical trials in ADAD aiming to prevent the onset of memory impairment and dementia. Dr. Bateman’s honors include the Scientific American 50 Award, recognizing the top 50 scientific achievements of 2006; the St. Louis Academy of Science Innovator of the Year Award; a 2011 Alzheimer’s Association Zenith Fellows Award; and the 2012 MetLife Promising Investigator Award. He serves as an editor and reviewer for many prominent scientific journals and is a sought-after lecturer nationally and internationally.